<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37798650</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-6512</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Stem cell research &amp; therapy</Title><ISOAbbreviation>Stem Cell Res Ther</ISOAbbreviation></Journal><ArticleTitle>Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.</ArticleTitle><Pagination><StartPage>287</StartPage><MedlinePgn>287</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">287</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13287-023-03522-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evolving mutations of the novel coronavirus continue to fuel up the pandemic. The virus affects the human respiratory system along with other body systems, causing several sequelae in the survivors of the disease, presented as post-COVID-19 syndrome or long-COVID-19. This protocol utilized Hope Biosciences' autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to evaluate safety and efficacy of HB-adMSC therapy to improve signs and symptoms associated with post-COVID-19 syndrome.</AbstractText><AbstractText Label="METHODS">Ten eligible subjects with post-COVID-19 syndrome were enrolled in the program for a duration of 40&#xa0;weeks who received 5 intravenous infusions of 2&#x2009;&#xd7;&#x2009;10<sup>8</sup> autologous HB-adMSCs each at week 0, 2, 6, 10 and 14 with a follow-up at week 18 and end of the study at week 40. Safety assessments included incidence of adverse and serious adverse events along with the laboratory measures of hematologic, hepatic, and renal function. Efficacy was examined by quality-of-life assessments, fatigue assessments, Visual analog scale (VAS) of symptoms and monitoring of respiration and oxygen saturation rates.</AbstractText><AbstractText Label="RESULTS">VAS scores and Fatigue Assessment scores (FAS) showed significant improvements post-treatment (P&#x2009;=&#x2009;0.0039, ES&#x2009;=&#x2009;0.91) compared to baseline. Respiration rates and oxygen saturation levels that were within the normal range at the baseline remained unchanged at the end of the study (EOS). Paired comparison between baseline and EOS for short-form-36 health survey questionnaire (SF-36) scores also showed improved quality-of-life with significant improvements in individual SF-36 evaluations. Mostly mild AEs were reported during the study period with no incidence of serious AEs. Also, no detrimental effects in laboratory values were seen.</AbstractText><AbstractText Label="CONCLUSIONS">The results of the expanded access program indicated that treatment with autologous HB-adMSCs resulted in significant improvements in the signs and symptoms associated with post-COVID-19 syndrome as assessed by VAS and FAS scores. Additionally, improvements in the patients' quality-of-life as demonstrated using SF-36 scores that also showed significant improvements in individual scaled scores. Overall, administration of multiple infusions of autologous HB-adMSCs is safe and efficacious for improvements in the quality-of life of patients with post-COVID-19 syndrome.</AbstractText><AbstractText Label="TRIAL REGISTRATION">Clinical trial registration number: NCT04798066. Registered on March 15, 2021. ( https://clinicaltrials.gov/ct2/show/NCT04798066?term=hope+biosciences&amp;cond=Post-COVID-19+Syndrome&amp;draw=2&amp;rank=2 ).</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vij</LastName><ForeName>Ridhima</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3130-5133</Identifier><AffiliationInfo><Affiliation>Hope Biosciences Research Foundation, 16700 Creek Bend Dr., Sugar Land, TX, 77478, USA. ridhima@hopebio.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hosu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hope Biosciences, Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyeonggeun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hope Biosciences, Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Thanh</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hope Biosciences Research Foundation, 16700 Creek Bend Dr., Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotfi</LastName><ForeName>Djamchid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hope Biosciences Research Foundation, 16700 Creek Bend Dr., Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hope Biosciences Research Foundation, 16700 Creek Bend Dr., Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Biosciences, Sugar Land, TX, 77478, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04798066</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stem Cell Res Ther</MedlineTA><NlmUniqueID>101527581</NlmUniqueID><ISSNLinking>1757-6512</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adipose-derived mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">Autologous</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Intravenous</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 syndrome</Keyword></KeywordList><CoiStatement>Ridhima Vij is an employee of Hope Biosciences Research Foundation and declares no competing interests that could have appeared to influence the work reported in this paper.&#xa0;Hosu Kim, Hyeonggeun Park and Donna Chang declare the following financial interests which may be considered as potential competing interests: The above listed authors are employees of Hope Biosciences LLC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37798650</ArticleId><ArticleId IdType="pmc">PMC10557203</ArticleId><ArticleId IdType="doi">10.1186/s13287-023-03522-1</ArticleId><ArticleId IdType="pii">10.1186/s13287-023-03522-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Helath Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on October 10 2022.&#xa0;</Citation></Reference><Reference><Citation>Rudrapal M, Khairnar SJ, Borse LB, Jadhav AG. Coronavirus disease-2019 (COVID-19): an updated review. Drug Res (Stuttg) 2020;70(9):389&#x2013;400. doi: 10.1055/a-1217-2397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1217-2397</ArticleId><ArticleId IdType="pmc">PMC7516369</ArticleId><ArticleId IdType="pubmed">32746481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548&#x2013;551. doi: 10.1002/jmv.25722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25722</ArticleId><ArticleId IdType="pmc">PMC7228250</ArticleId><ArticleId IdType="pubmed">32096567</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552&#x2013;555. doi: 10.1002/jmv.25728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25728</ArticleId><ArticleId IdType="pmc">PMC7228394</ArticleId><ArticleId IdType="pubmed">32104915</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. 2021;93(5):2555&#x2013;2556. doi: 10.1002/jmv.26624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay SV, Bartoces M, Gouin K, Kabbani S, Hicks LA. Antibiotic prescriptions associated with COVID-19 outpatient visits among medicare beneficiaries, April 2020 to April 2021. JAMA. 2022;327(20):2018&#x2013;2019. doi: 10.1001/jama.2022.5471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.5471</ArticleId><ArticleId IdType="pmc">PMC8994157</ArticleId><ArticleId IdType="pubmed">35394497</ArticleId></ArticleIdList></Reference><Reference><Citation>Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Pharmacol Res. 2020;156:104761. doi: 10.1016/j.phrs.2020.104761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104761</ArticleId><ArticleId IdType="pmc">PMC7102548</ArticleId><ArticleId IdType="pubmed">32205232</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490&#x2013;9496. doi: 10.1073/pnas.2004168117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2004168117</ArticleId><ArticleId IdType="pmc">PMC7196837</ArticleId><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J, Mo X, Zhang X, Xun J, Chen X, Liu Y, et al. Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. Expert Rev Respir Med. 2022;16(1):79&#x2013;89. doi: 10.1080/17476348.2021.1983429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2021.1983429</ArticleId><ArticleId IdType="pmc">PMC8500308</ArticleId><ArticleId IdType="pubmed">34541972</ArticleId></ArticleIdList></Reference><Reference><Citation>Florindo HF, Kleiner R, Vaskovich-Koubi D, Ac&#xfa;rcio RC, Carreira B, Yeini E, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020;15(8):630&#x2013;645. doi: 10.1038/s41565-020-0732-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-020-0732-3</ArticleId><ArticleId IdType="pmc">PMC7355525</ArticleId><ArticleId IdType="pubmed">32661375</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado Cde V, Telles PD, Nascimento IL. Immunological characteristics of mesenchymal stem cells. Rev Bras Hematol Hemoter. 2013;35(1):62&#x2013;67. doi: 10.5581/1516-8484.20130017.</Citation><ArticleIdList><ArticleId IdType="doi">10.5581/1516-8484.20130017</ArticleId><ArticleId IdType="pmc">PMC3621638</ArticleId><ArticleId IdType="pubmed">23580887</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838&#x2013;3843. doi: 10.1182/blood.V99.10.3838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.10.3838</ArticleId><ArticleId IdType="pubmed">11986244</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11&#x2013;20. doi: 10.1046/j.1365-3083.2003.01176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-3083.2003.01176.x</ArticleId><ArticleId IdType="pubmed">12542793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann S, Moradi B, Frank S, Dreher T, Kammerer PW, Richter W, et al. FGF-2 addition during expansion of human bone marrow-derived stromal cells alters MSC surface marker distribution and chondrogenic differentiation potential. Cell Prolif. 2013;46(4):396&#x2013;407. doi: 10.1111/cpr.12046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.12046</ArticleId><ArticleId IdType="pmc">PMC6495732</ArticleId><ArticleId IdType="pubmed">23869761</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveri RS, Bello S, Biering-Sorensen F. Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: systematic review with meta-analyses of rat models. Neurobiol Dis. 2014;62:338&#x2013;353. doi: 10.1016/j.nbd.2013.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.10.014</ArticleId><ArticleId IdType="pubmed">24148857</ArticleId></ArticleIdList></Reference><Reference><Citation>Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105(7):2821&#x2013;2827. doi: 10.1182/blood-2004-09-3696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-09-3696</ArticleId><ArticleId IdType="pubmed">15591115</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6:457&#x2013;478. doi: 10.1146/annurev-pathol-011110-130230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-011110-130230</ArticleId><ArticleId IdType="pubmed">21073342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankeny DP, McTigue DM, Jakeman LB. Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats. Exp Neurol. 2004;190(1):17&#x2013;31. doi: 10.1016/j.expneurol.2004.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.05.045</ArticleId><ArticleId IdType="pubmed">15473977</ArticleId></ArticleIdList></Reference><Reference><Citation>Nad OE, Pekkoc-Uyanik KC, Alpaydin N, Gulay GR, Simsek M. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. Stem Cell Rev Rep. 2021;17(5):1917&#x2013;25. doi: 10.1007/s12015-021-10214-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-021-10214-x</ArticleId><ArticleId IdType="pmc">PMC8317476</ArticleId><ArticleId IdType="pubmed">34319510</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. doi: 10.1186/s13287-020-01875-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01875-5</ArticleId><ArticleId IdType="pmc">PMC7432540</ArticleId><ArticleId IdType="pubmed">32811531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. 2021;10(9):1279&#x2013;1287. doi: 10.1002/sctm.21-0046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.21-0046</ArticleId><ArticleId IdType="pmc">PMC8242692</ArticleId><ArticleId IdType="pubmed">34102020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei F, Kong D, Li T, Li A, Tan Y, Fang J, et al. Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19. Clinics (Sao Paulo) 2021;76:e2604. doi: 10.6061/clinics/2021/e2604.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2021/e2604</ArticleId><ArticleId IdType="pmc">PMC8101688</ArticleId><ArticleId IdType="pubmed">34008772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:103789. doi: 10.1016/j.ebiom.2021.103789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103789</ArticleId><ArticleId IdType="pmc">PMC8709782</ArticleId><ArticleId IdType="pubmed">34963099</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu W, Wang Z, Engelberg-Cook E, Yan D, Siddik AB, Bu G, et al. Efficacy and safety of MSC cell therapies for hospitalized patients with COVID-19: a systematic review and meta-analysis. Stem Cells Transl Med. 2022;11(7):688&#x2013;703. doi: 10.1093/stcltm/szac032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/stcltm/szac032</ArticleId><ArticleId IdType="pmc">PMC9299515</ArticleId><ArticleId IdType="pubmed">35640138</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC) Allergo J Int. 2017;26(1):16&#x2013;24. doi: 10.1007/s40629-016-0006-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40629-016-0006-7</ArticleId><ArticleId IdType="pmc">PMC5288410</ArticleId><ArticleId IdType="pubmed">28217433</ArticleId></ArticleIdList></Reference><Reference><Citation>Michielsen HJ, Vries JD, Heck GLV, Vijver FJRVD, Sijtsma K. Examination of the dimensionality of Fatigue. Eur J Psychol Assess. 2004;20(1):39&#x2013;48. doi: 10.1027/1015-5759.20.1.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1027/1015-5759.20.1.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal R. Meta-Analytic Procedures for Social Research. Thousand Oaks, California1991. Available from: https://methods.sagepub.com/book/meta-analytic-procedures-for-social-research.</Citation></Reference><Reference><Citation>Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141(1):2&#x2013;18. doi: 10.1037/a0024338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0024338</ArticleId><ArticleId IdType="pubmed">21823805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. JAMA Netw Open. 2021;4(9):e2127403-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021;11(2):e297. doi: 10.1002/ctm2.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.297</ArticleId><ArticleId IdType="pmc">PMC7839959</ArticleId><ArticleId IdType="pubmed">33634996</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216&#x2013;228. doi: 10.14336/AD.2020.0228.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0228</ArticleId><ArticleId IdType="pmc">PMC7069465</ArticleId><ArticleId IdType="pubmed">32257537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660&#x2013;673. doi: 10.1002/sctm.20-0472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.20-0472</ArticleId><ArticleId IdType="pmc">PMC8046040</ArticleId><ArticleId IdType="pubmed">33400390</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Guijo F, Garc&#xed;a-Arranz M, L&#xf3;pez-Parra M, Monedero P, Mata-Mart&#xed;nez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. 2020;25:100454. doi: 10.1016/j.eclinm.2020.100454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100454</ArticleId><ArticleId IdType="pmc">PMC7348610</ArticleId><ArticleId IdType="pubmed">32838232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15(1):1&#x2013;10. doi: 10.1186/1465-9921-15-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-15-39</ArticleId><ArticleId IdType="pmc">PMC3994204</ArticleId><ArticleId IdType="pubmed">24708472</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>